123 related articles for article (PubMed ID: 37782888)
1. Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical Outcome.
Sharma NR; Lo SK; Hendifar A; Othman MO; Patel K; Mendoza-Ladd A; Verco S; Maulhardt HA; Verco J; Wendt A; Marin A; Schmidt CM; diZerega G
Pancreas; 2023 Mar; 52(3):e179-e187. PubMed ID: 37782888
[TBL] [Abstract][Full Text] [Related]
2. Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts.
Othman M; Patel K; Krishna SG; Mendoza-Ladd A; Verco S; Abidi W; Verco J; Wendt A; diZerega G
Endosc Int Open; 2022 Dec; 10(12):E1517-E1525. PubMed ID: 36531683
[No Abstract] [Full Text] [Related]
3. Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: Insights from an expanded access protocol.
Krishna SG; Ardeshna DR; Shah ZK; Hart PA; Culp S; Jones D; Chen W; Papachristou GI; Han S; Lee PJ; Shah H; Pawlik TM; Dillhoff M; Manilchuk A; Cloyd J JM; Ejaz A; Fry M; Noonan AM
Pancreatology; 2024 Mar; 24(2):289-297. PubMed ID: 38238194
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies.
diZerega GS; Maulhardt HA; Verco SJ; Marin AM; Baltezor MJ; Mauro SA; Iacobucci MA
Oncol Ther; 2024 Mar; 12(1):31-55. PubMed ID: 38289576
[TBL] [Abstract][Full Text] [Related]
5. Results of a single-arm pilot study of
Ross PJ; Wasan HS; Croagh D; Nikfarjam M; Nguyen N; Aghmesheh M; Nagrial AM; Bartholomeusz D; Hendlisz A; Ajithkumar T; Iwuji C; Wilson NE; Turner DM; James DC; Young E; Harris MT
ESMO Open; 2022 Feb; 7(1):100356. PubMed ID: 34953400
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Treatment of Melanoma Tumors with Large Surface Area Microparticle Paclitaxel and Synergy with Immune Checkpoint Inhibition.
Maulhardt HA; Marin AM; diZerega GS
Int J Nanomedicine; 2024; 19():689-697. PubMed ID: 38283196
[TBL] [Abstract][Full Text] [Related]
7. Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer.
Kates M; Mansour AM; Lamm DL; Shore N; Maulhardt H; Wendt A; Verco J; Marin A; Dewnani K; Verco S; diZerega GS
J Urol; 2022 Oct; 208(4):821-829. PubMed ID: 35574612
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant
Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
[TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
10. Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies.
Maulhardt H; Verco S; Baltezor M; Marin A; diZerega G
Drug Deliv Transl Res; 2023 Feb; 13(2):503-519. PubMed ID: 36058988
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
[TBL] [Abstract][Full Text] [Related]
12. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
13. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.
Hanna N; Ohana P; Konikoff FM; Leichtmann G; Hubert A; Appelbaum L; Kopelman Y; Czerniak A; Hochberg A
Cancer Gene Ther; 2012 Jun; 19(6):374-81. PubMed ID: 22498722
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
[TBL] [Abstract][Full Text] [Related]
16. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
17. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
[TBL] [Abstract][Full Text] [Related]
18. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Yamaguchi J; Yokoyama Y; Fujii T; Yamada S; Takami H; Kawashima H; Ohno E; Ishikawa T; Maeda O; Ogawa H; Kodera Y; Nagino M; Ebata T
Ann Surg; 2022 Jun; 275(6):1043-1049. PubMed ID: 35258510
[TBL] [Abstract][Full Text] [Related]
19. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
[TBL] [Abstract][Full Text] [Related]
20. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]